Shares of Cipla dipped 7 per cent to Rs 956.20 on the BSE in Monday’s intra-day trade after the company said that the United States Food and Drug Administration (USFDA) issued Form 483 with 8 observations after the inspection of its Pithampur manufacturing facilities.
USFDA conducted a current Good Manufacturing Practices (cGMP) inspection at the company’s Pithampur manufacturing facility from 6th – 17th February, 2023, Cipla said in an exchange filing.
On conclusion of the inspection, the company has received 8 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time, Cipla said.
At 09:23 AM; Cipla quoted 5 per cent lower at Rs 971.60, as compared to 0.16 per cent rise in the S&P BSE Sensex. The stock of pharmaceutical company was trading at its lowest level since July 2022.
Also Read : Indians spent nearly $10 billion on foreign travel in April-December
In past one month, Cipla has underperformed the market, by falling 11 per cent, as against 1 per cent gain in the benchmark index.
Meanwhile, after announcement of October-December quarter (Q3FY23) earnings by Cipla on January 26, analysts at Prabhudas Lilladher reduced their FY24/FY25 earnings by ~4 per cent factoring in delay in key US launches and lower margins.
“Cipla’s Q3FY23 EBITDA was largely in-line with our estimates (24 per cent) aided by higher GMs and strong US sales. We expect 18 per cent EPS CAGR over FY23-25E given resilient earnings, improving US visibility and strong free cash flow generation,” the brokerage firm said.
Analysts further said they continue to remain positive on Cipla’s growth across key segments including India and US given strong traction in respiratory and other portfolio, ExCOVID, domestic formulation to potentially grow +10 per cent going forward and sustainability of current US revs, backed by potential key launches.